Phio Pharmaceuticals (PHIO) Net Cash Flow (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Net Cash Flow came in at -$4.0 million in Q1 2026, down 150.66% YoY from $7.9 million in Q1 2025, and down 138.74% on a QoQ basis from $10.3 million in Q4 2025.
Phio Pharmaceuticals (PHIO) Net Cash Flow (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Net Cash Flow data on file, last reported at -$4.0 million in Q1 2026.
- Quarterly Net Cash Flow fell 150.66% year-over-year to -$4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 44.83% YoY) and the FY2025 annual result came in at $15.6 million, up 603.51% from the prior year.
- Net Cash Flow declined to -$4.0 million in Q1 2026, from $10.3 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $10.3 million in Q4 2025 to a low of -$4.0 million in Q1 2026.
- A 5-year average of -$416235.3 and a median of -$2.0 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow sank 178.21% — and 2025, when it jumped 129175.0%.
- Tracing PHIO's Net Cash Flow over 5 years: stood at -$2.7 million in 2022, then jumped by 101.22% to $33000.0 in 2023, then sank by 124.24% to -$8000.0 in 2024, then jumped by 129175.0% to $10.3 million in 2025, then sank by 138.74% to -$4.0 million in 2026.
- The last three Net Cash Flow figures came in at -$4.0 million (Q1 2026), $10.3 million (Q4 2025), and -$70000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Phio Pharmaceuticals | 13.77 Mn | 13.77 Mn | - | -4.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.04 Mn |
| Jun 30, 2026 | -4.04 Mn |
| Mar 31, 2026 | -4.00 Mn |
| Mar 31, 2026 | -4.00 Mn |
| Dec 31, 2025 | 10.33 Mn |
| Dec 31, 2025 | 10.33 Mn |
| Sep 30, 2025 | -70,000.00 |
| Sep 30, 2025 | -70,000.00 |
| Jun 30, 2025 | -2.50 Mn |
| Jun 30, 2025 | -2.50 Mn |
| Mar 31, 2025 | 7.90 Mn |
| Mar 31, 2025 | 7.90 Mn |
| Dec 31, 2024 | -8,000.00 |
| Dec 31, 2024 | -8,000.00 |
| Sep 30, 2024 | 692,000.00 |
| Sep 30, 2024 | 692,000.00 |
| Jun 30, 2024 | -1.78 Mn |
| Jun 30, 2024 | -1.78 Mn |
| Mar 31, 2024 | -2.02 Mn |
| Mar 31, 2024 | -2.02 Mn |